| Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 |
| Gross Profit | $ -11.54K | $ -7.95K | $ -8.29K | $ -3.64K | $ 0.00 |
| Operating Income | $ -1.85M | $ -2.22M | $ -3.82M | $ -2.13M | $ -4.21M |
| EBITDA | $ -1.84M | $ -2.22M | $ -3.82M | $ -2.13M | $ -4.21M |
| Net Income | $ -2.12M | $ -2.37M | $ -4.28M | $ -2.46M | $ -4.35M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 509.91K | $ 5.15K | $ 26.09K | $ 295.40K | $ 72.36K |
| Total Assets | $ 658.55K | $ 138.69K | $ 137.64K | $ 370.94K | $ 119.29K |
| Total Debt | $ 1.25M | $ 1.09M | $ 1.93M | $ 2.17M | $ 2.12M |
| Net Debt | $ 740.75K | $ 1.09M | $ 1.90M | $ 1.87M | $ 2.05M |
| Total Liabilities | $ 3.25M | $ 1.93M | $ 3.25M | $ 3.66M | $ 3.28M |
| Stockholders' Equity | $ -2.59M | $ -1.79M | $ -2.43M | $ -2.70M | $ -2.76M |
| Cash Flow | |||||
| Free Cash Flow | $ -526.46K | $ -83.93K | $ -819.68K | $ -1.84M | $ -1.73M |
| Operating Cash Flow | $ -526.46K | $ -55.74K | $ -775.38K | $ -1.81M | $ -1.70M |
| Investing Cash Flow | $ -23.09K | $ -28.20K | $ -44.30K | $ -32.25K | $ -36.93K |
| Financing Cash Flow | $ 1.05M | $ 63.00K | $ 550.36K | $ 2.06M | $ 1.76M |
Bioxytran Forecast EPS vs Actual EPS
Currently, no data available
Please return soon. This page is being updated.